Post-Surgical Wound Dehiscence: Role of Amniotic Allografts in Complex Closure

Wound dehiscence remains one of the most consequential complications in operative care. A partial or total separation of previously approximated wound edges, dehiscence can extend hospital stays, increase infection risk, and necessitate reoperation. For general surgeons, orthopedic teams, and podiatrists managing complex closures, the question is not whether dehiscence occurs, but which adjunctive measures may support healing in patients whose baseline risk profile already tilts toward failure.

Amniotic membrane allografts have emerged as one such adjunct. Regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under FDA 21 CFR Part 1271 and Section 361 of the Public Health Service Act, these materials are not drugs or devices. They are minimally manipulated tissues intended for homologous use, and their role in surgical wound management is increasingly documented across foot and ankle, orthopedic, and reconstructive literature. This article examines dehiscence risk factors, the biologic rationale for amniotic membrane in surgical wounds, and the evidence base that informs selective use.

Dehiscence Risk Factors in Surgical Practice

Dehiscence is multifactorial. Patient-level risks include obesity, diabetes, malnutrition, hypoalbuminemia, smoking, advanced age, malignancy, and chronic corticosteroid use. Operative factors include emergency surgery, prolonged operative time, bowel surgery, surgical site infection, and excessive wound tension. In orthopedic and podiatric settings, additional risks include thin dorsal soft tissue, prior incision compromise, hardware prominence, and high-shear closures over mobile joints.

A 2024 retrospective cohort of 204 women undergoing open gynecologic oncologic surgery found surgical site infection in 24.5% of cases and fascial dehiscence in 8.8%. Notably, operative duration was independently associated with both complications only when bowel surgery was performed, with each additional hour increasing dehiscence odds approximately 2.5-fold. BMI also mattered, though its effect was attenuated with advancing age. These interaction effects are clinically relevant: risk is rarely additive; it is often multiplicative when comorbidities and operative complexity coincide.

In foot and ankle surgery, published complication rates underscore the problem. Elective foot and ankle procedures carry wound complication rates near 17%. Total ankle arthroplasty reports wound complication rates of 15% or higher. Ankle fracture open reduction and internal fixation carries a 5% wound complication rate, with peripheral vascular disease, open wounds, age over 70, and elevated ASA status as independent predictors. For surgeons operating on patients who check multiple risk boxes, the threshold for considering adjunctive support should be low.

Mechanism of Amniotic Membrane in Surgical Wounds

Human amniotic membrane is an avascular tissue 0.02 to 0.5 mm thick, composed of an epithelial layer, basement membrane, compact collagen layer, fibroblast layer, and spongy zona. It is immunologically privileged, expressing negligible HLA class II and upregulating HLA-G, which engages inhibitory receptors on immune cells and promotes tolerance. This low immunogenic profile means allograft rejection is rare, even without systemic immunosuppression.

The biologic activity of amniotic membrane extends beyond passive coverage. The tissue is rich in growth factors including hepatocyte growth factor, keratinocyte growth factor, epidermal growth factor, and basic fibroblast growth factor. It contains extracellular matrix proteins, collagen IV and VII, laminin, fibronectin, and hyaluronic acid, providing a scaffold for cell adhesion and migration. Matrix metalloproteinase inhibitors, including tissue inhibitors of metalloproteinases, help prevent excessive matrix degradation during the remodeling phase.

Immunomodulation is perhaps the most relevant mechanism in high-risk surgical closures. Amniotic membrane reduces secretion of pro-inflammatory cytokines, including TNF-alpha, IFN-gamma, IL-6, and IL-17, by monocytes and lymphocytes. It drives macrophage polarization toward the M2 anti-inflammatory phenotype, downregulating IL-1 beta, IL-12, and TNF-alpha while upregulating IL-10. Migration inhibitory factor prevents neutrophil and macrophage infiltration into tissues. The net effect is a dampened inflammatory response that may protect fragile wound edges from the cascade of inflammation-driven tissue breakdown.

Anti-fibrotic properties are also clinically relevant. Amniotic membrane suppresses TGF-beta signaling in fibroblasts, preventing myofibroblast differentiation and excessive scar deposition. In procedures where scar tethering could limit function, such as tendon or nerve surgery, this property may offer benefit beyond simple wound coverage.

Clinical Evidence in Surgical Settings

Human surgical data are most developed in foot and ankle applications, with emerging evidence in nerve wrapping and reconstructive surgery. In total ankle arthroplasty, Gessner and colleagues evaluated cryopreserved amniotic membrane-umbilical cord allograft placement at closure in 104 patients and reported faster skin healing versus controls, with mean time to healing reduced from 40 days to 28.5 days. The study was not powered to show fewer major reoperations, but it supports the concept that biologic augmentation may matter most in soft-tissue-vulnerable anterior ankle incisions.

In hallux rigidus surgery, Galli and colleagues reported a prospective randomized comparison of cheilectomy with or without cryopreserved amniotic membrane-umbilical cord. At one year, the biologic group showed better AOFAS and Foot Function Index outcomes, although pain scores improved in both groups and range-of-motion differences were minimal. This pattern, improved functional recovery without dramatic early separation, is consistent across much of the perioperative amniotic membrane literature.

For broader reconstructive lower-extremity surgery, Tacktill and colleagues described 21 consecutive foot and ankle cases in which dehydrated amnion/chorion was placed over deep tissues during closure. Functional scores improved substantially over follow-up, and the cohort had no wound dehiscence. As a noncomparative series, it should not be read as definitive proof, but it reinforces feasibility in complex lower-extremity reconstruction and aligns with the broader observation that amniotic membrane placement during deep closure may support wound integrity in high-risk patients.

Outside the foot and ankle, the biologic rationale is strongest where scar formation compromises function. In cubital tunnel surgery, Gaspar and colleagues found that human amniotic membrane wrapping of the ulnar nerve reduced recurrent paresthesia symptoms. In traumatic peripheral nerve repair, Assaf and colleagues reported favorable nerve regeneration and recovery findings after amniotic wrapping. A 2023 systematic review by Walker and colleagues concluded that available studies suggest potential benefit for reducing epidural adhesions and improving postoperative outcomes, while also emphasizing that preparations and indications remain too variable for firm conclusions.

A 2022 case report by Restaino and colleagues described the use of human amniotic membrane for myocutaneous dehiscence after radical vulvar cancer surgery. Two months postoperatively, following curettage and negative pressure therapy, a patch of human amniotic membrane was implanted. The procedure was performed without complications, and the authors reported marked improvement in the surgical wound. While a single case does not establish efficacy, it illustrates the practical application of amniotic membrane in dehisced wounds where standard closure has already failed.

Protocol Considerations for Complex Closures

Case selection should drive decision-making. The strongest rationale exists in revision surgery, anterior ankle approaches, exposed tendon or bone, areas of thin dorsal soft tissue, high-shear closures, and procedures where scar tethering could limit function. Diabetes, smoking history, edema, prior incision compromise, neuropathy, and hardware prominence all raise the threshold for considering biologic reinforcement.

Intraoperatively, most published foot and ankle series place the graft during deep closure rather than on top of the final epithelial surface. The goal is to create a biologically active interface over periosteal, capsular, retinacular, tendon, or neurovascular structures while preserving standard layered closure. The graft should be cut to fit the target zone, laid without bunching, and secured according to the product instructions for use. Avoid folding excess material into confined spaces that could increase dead space or alter glide mechanics.

Postoperatively, management should remain disciplined: edema control, offloading, incision surveillance, and prompt escalation for drainage or skin edge compromise. Documentation should clearly identify the operative problem the allograft was intended to address, for example, high-risk anterior ankle closure, exposed extensor mechanism, revision tendon bed, or scar-prone nerve decompression field. This documentation supports both clinical accountability and any subsequent payer inquiry.

Regulatory Classification

Amniotic membrane products marketed as wound coverings or barriers are regulated as 361 HCT/Ps under FDA 21 CFR Part 1271 and Section 361 of the Public Health Service Act. To qualify for this pathway, the product must be minimally manipulated, intended for homologous use, not combined with other cells or tissues, and have a localized effect without systemic dependence on the metabolic activity of living cells. Products that do not meet all criteria in 21 CFR 1271.10(a) are regulated as drugs, devices, or biological products and require premarket review.

Clinicians should verify that any amniotic membrane product they consider carries appropriate 361 HCT/P registration and is labeled for the intended use. Off-label claims, including assertions of preventing dehiscence or guaranteeing improved outcomes, are not supported by the regulatory framework and should be avoided in documentation, marketing, and patient communication.

References

1. Nugent E, et al. Determining risk factors for surgical wound dehiscence: a prospective cohort study. Int Wound J. 2021;18(4):456-463. (PMID: 33150789; PMCID: PMC7950784)
2. PMC11674529. Risk Factors for Surgical Wound Infection and Fascial Dehiscence After Open Gynecologic Oncologic Surgery: A Retrospective Cohort Study. Cancers. 2024;16(18). (PMCID: PMC11674529)
3. Wound Dehiscence. StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. (NBK551712)
4. PMC12316762. Amniotic Membrane Transplantation for Wound Healing, Tissue Regeneration and Immune Modulation. Stem Cell Rev Rep. 2025. (PMCID: PMC12316762)
5. PMC4930235. Amniotic membrane can be a valid source for wound healing. Int Wound J. 2016;13(6):1127-1130. (PMCID: PMC4930235)
6. PMC9705161. Tacktill JZ, Rasor Z, Adams J, et al. Wound repair, safety, and functional outcomes in reconstructive lower extremity foot and ankle surgery using a dehydrated amnion/chorion allograft membrane. Int Wound J. 2022;19(8):2027-2036. (PMCID: PMC9705161)
7. Gessner IH, et al. Effects of Cryopreserved Amniotic Membrane-Umbilical Cord Allograft on Total Ankle Arthroplasty Wound Healing. J Foot Ankle Surg. 2019;58(2):236-243.
8. Galli SH, Ferguson CM, Davis WH, et al. Cheilectomy With or Without Cryopreserved Amniotic Membrane-Umbilical Cord Allograft for Hallux Rigidus. Foot Ankle Orthop. 2021;6(1):2473011420967999.
9. PMC9539543. Restaino S, et al. Human amniotic membrane for myocutaneous dehiscence after a radical surgical treatment of vulvar cancer: a case report. Front Oncol. 2022;12:1009884. (PMCID: PMC9539543)
10. Gaspar MP, et al. Human Amniotic Membrane Wrapping of the Ulnar Nerve During Cubital Tunnel Surgery Reduces Recurrence of Symptoms. J Hand Surg Glob Online. 2022;5(2):148-153.
11. Assaf M, et al. Effect of Amniotic Membrane Nerve Wrapping in Final Results of Traumatic Peripheral Nerve Repair. World J Plast Surg. 2022;11(2):90-97.
12. Walker M, et al. The Effect of Amniotic Tissue on Spinal Interventions: A Systematic Review. Int J Spine Surg. 2023;17(1):32-41.
13. U.S. Food and Drug Administration. 21 CFR Part 1271: Human Cells, Tissues, and Cellular and Tissue-Based Products. Accessed May 2026.
14. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. Guidance for Industry. December 2017.